Steven Kanner
Directeur Technique/Scientifique/R&D chez CARIBOU BIOSCIENCES, INC.
Fortune : 1 M $ au 30/04/2024
Postes actifs de Steven Kanner
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/06/2017 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Directeur/Membre du Conseil | 10/10/2023 | - |
| Independent Dir/Board Member | 10/10/2023 | - |
Historique de carrière de Steven Kanner
Anciens postes connus de Steven Kanner
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19/09/2013 | 01/06/2017 |
Formation de Steven Kanner
| University of California, Berkeley | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Bourse
- Insiders
- Steven Kanner
- Expérience
